ArticleJournal of medical cases2026
Local Urticarial Reaction Above the Site of an Intravenous Cannula: Possible Allergy to Remimazolam in a Fourteen-Year-Old Adolescent.
Article in Journal of medical cases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Remimazolam-Induced Anaphylaxis After Spinal Anesthesia: A Case Report and Literature Review.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Remimazolam is an intravenous, ultra-short acting benzodiazepine that has been most commonly used for procedural sedation. It received approval for procedural sedation in adults by the United States Food and Drug Administration (FDA) in 2020. Despite an overall favorable safety profile, anecdotal experience has suggested a potential for allergic phenomena, including anaphylaxis. We present a 14-year-old patient who developed a localized reaction with urticaria in an extremity following the administration of remimazolam. Although we cannot definitively identify remimazolam as the cause of the hypersensitivity reaction and no formal allergy testing was completed, the temporal association of its administration with the development of the local reaction suggests a possible relationship. Previous reports of allergic reactions following the administration of remimazolam are reviewed, mechanisms discussed, and guidelines for clinical care presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.